Trial · NCT04697381
Results by group27
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 27
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to Month 12 in Lean Body Mass Measured by Dual-Energy X-ray Absorptiometry (DEXA): Adult Cohort | Adult Cohort | 3.09 | 95% Confidence Interval 1.85 to 4.33 | Percentage of body mass | |
| Change From Baseline to Month 12 in Lean Body Mass Measured by DEXA: GH Naive Pediatric and GH Treated Pediatric Cohort | GH Naive Pediatric Cohort | 4.59 | Standard Deviation 4.490 | Percentage of body mass | |
| Change From Baseline to Month 12 in Lean Body Mass Measured by DEXA: GH Naive Pediatric and GH Treated Pediatric Cohort | GH Treated Pediatric Cohort | -1.34 | Standard Deviation 3.238 | Percentage of body mass | |
| Change From Baseline to Month 12 in Lean Body Mass Measured by Bioelectrical Impedance Analysis (BIA)-Adult Cohort | Adult Cohort | 2.03 | 95% Confidence Interval -0.67 to 4.73 | Percentage of body mass | |
| Change From Baseline to Month 12 in Lean Body Mass Measured by BIA-GH Naive Pediatric and GH Treated Pediatric Cohort | GH Naive Pediatric Cohort | 3.32 | Standard Deviation 3.867 | Percentage of body mass | |
| Change From Baseline to Month 12 in Lean Body Mass Measured by BIA-GH Naive Pediatric and GH Treated Pediatric Cohort | GH Treated Pediatric Cohort | 0.58 | Standard Deviation 4.711 | Percentage of body mass | |
| Change From Baseline to Month 12 in Body Fat (Percentage) Measured by DEXA: Adult Cohort | Adult Cohort | -3.09 | 95% Confidence Interval -4.33 to -1.85 | Percentage of body fat | |
| Change From Baseline to Month 12 in Body Fat (Percentage) Measured by DEXA: GH Naive Pediatric and GH Treated Pediatric Cohort | GH Naive Pediatric Cohort | -4.59 | Standard Deviation 4.490 | Percentage of body fat | |
| Change From Baseline to Month 12 in Body Fat (Percentage) Measured by DEXA: GH Naive Pediatric and GH Treated Pediatric Cohort | GH Treated Pediatric Cohort | 1.34 | Standard Deviation 3.238 | Percentage of body fat | |
| Change From Baseline to Month 12 in Adipose Tissue Distribution Measured by Abdominal Computed Tomography (CT) | GH Naive Pediatric Cohort | Change at Month 12, SAT | 60.423 | Standard Deviation 138.2001 | Centimeter square (cm^2) |
| Change From Baseline to Month 12 in Adipose Tissue Distribution Measured by Abdominal Computed Tomography (CT) | GH Treated Pediatric Cohort | Change at Month 12, SAT | 102.222 | Standard Deviation 211.9111 | Centimeter square (cm^2) |
| Change From Baseline to Month 12 in Adipose Tissue Distribution Measured by Abdominal Computed Tomography (CT) | Adult Cohort | Change at Month 12, SAT | -13.764 | Standard Deviation 31.0212 | Centimeter square (cm^2) |
| Change From Baseline to Month 12 in Adipose Tissue Distribution Measured by Abdominal Computed Tomography (CT) | GH Naive Pediatric Cohort | Change at Month 12, VAT | 4.825 | Standard Deviation 13.5401 | Centimeter square (cm^2) |
| Change From Baseline to Month 12 in Adipose Tissue Distribution Measured by Abdominal Computed Tomography (CT) | GH Treated Pediatric Cohort | Change at Month 12, VAT | -13.403 | Standard Deviation 28.5490 | Centimeter square (cm^2) |
| Change From Baseline to Month 12 in Adipose Tissue Distribution Measured by Abdominal Computed Tomography (CT) | Adult Cohort | Change at Month 12, VAT | -4.040 | Standard Deviation 16.8243 | Centimeter square (cm^2) |
| Change From Baseline to Month 6 in Lean Body Mass Measured by DEXA: Adult Cohort Only | Adult Cohort | 2.38 | 95% Confidence Interval 1.30 to 3.46 | Percentage of body mass | |
| Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events | GH Naive Pediatric Cohort | TEAEs | 5 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events | GH Treated Pediatric Cohort | TEAEs | 7 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events | Adult Cohort | TEAEs | 19 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events | GH Naive Pediatric Cohort | Treatment Emergent SAEs | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04697381/results